Andrew G. Long
Known title: EVP, CFOCIK: 0001714880
Associated companies
Transaction History
| ACH | ▼ Sell | Gift | 47,908 | $0 | 11/19/2025 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 19,081 | $134K | 5/15/2025 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 4,578 | $46K | 3/20/2025 | View on chart |
| ACH | ▲ Buy | Grant | 134,121 | $0 | 3/3/2025 | View on chart |
| ACH | ▼ Sell | Gift | 70,898 | $0 | 8/8/2024 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 27,372 | $541K | 5/15/2024 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 22,785 | $569K | 3/15/2024 | View on chart |
| ACH | ▲ Buy | Grant | 50,731 | $0 | 3/1/2024 | View on chart |
| ACH | ▼ Sell | Gift | 115,555 | $0 | 5/19/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 8,266 | $155K | 5/15/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 7,186 | $132K | 5/11/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 33,471 | $437K | 3/15/2023 | View on chart |
| ACH | ▲ Buy | Grant | 139,249 | $0 | 3/1/2023 | View on chart |
| ACH | ▲ Buy | Grant | 55,654 | $0 | 3/1/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 7,442 | $158K | 11/11/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 4,267 | $154K | 5/16/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 7,185 | $270K | 5/11/2022 | View on chart |
| ACH | ▲ Buy | Grant | 26,889 | $0 | 3/3/2022 | View on chart |
| ACH | ▲ Buy | Grant | 96,552 | $0 | 2/9/2022 | View on chart |
| ACH | ▼ Sell | Open Market | 11,882 | $502K | 11/12/2021 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 5,828 | $244K | 11/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice
Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.